ArticleLancet (London, England)2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
Open access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Lancet (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Marburg virus disease outbreaks, mathematical models, and disease parameters: a systematic review.The Lancet. Infectious diseases · 2024Pooled it
- Emergence of Marburg virus disease in Ethiopia: Implications for public health preparedness and its impact on Ethiopia's health system.PLoS neglected tropical diseases · 2026Review
- The newly developed porcine-origin parainfluenza virus PIV5-JS17 serves as an exogenous gene delivery system for swine.Journal of virology · 2026Article
- Marburg and Sudan virus outbreaks: are we any closer to a pan-filovirus vaccine?Tropical diseases, travel medicine and vaccines · 2026Review
- Article
- Review
- Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification.Nature communications · 2025Article
- A review of post-exposure strategies for high-consequence viral pathogens in the laboratory.Clinical microbiology reviews · 2025Review
- Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025Review
- Ethiopia's first Marburg virus outbreak - Implications for emerging hemorrhagic fevers in Africa.New microbes and new infections · 2025Article
- Marburg virus glycoprotein mRNA vaccine is more protective than a virus-like particle-forming mRNA vaccine.The Journal of clinical investigation · 2025Article
- Article
- Increasing Occurrence of Marburg Virus Outbreaks in Africa: Risk Assessment for Public Health.Microbial biotechnology · 2025Review
- Immunogenicity of differentially glycosylated Marburg virus glycoproteins expressed in mammalian and insect cells.Virology journal · 2025Article
- Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modification.bioRxiv : the preprint server for biology · 2025Article
- Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses.Nature communications · 2025Article
- Marburg virus outbreak: a global health threat, zoonotic risks, and the urgent need for international action.Virusdisease · 2025Article
- Tanzania confirms its second MVD outbreak: A constantly emerging outbreak calls for effective countermeasures in light of one health approach and preparedness to counter future epidemics.One health (Amsterdam, Netherlands) · 2025Article
- Four decades of adenovirus gene transfer vectors: History and current use.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Marburg Virus Disease: A Narrative Review.Health science reports · 2025Article
Corrections and comments
- Commented on by
Authors and funding
51 authors at 4 institutions in 1 country.
Melinda J HamerWalter Reed Army Institute of Research, Silver Spring, MD, USA; Department of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Katherine V HouserVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: katherine.houser@nih.gov.
Amelia R HofstetterVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ana M Ortega-VillaBiostatistics Research Branch, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Christine LeeWalter Reed Army Institute of Research, Silver Spring, MD, USA.
Anne PrestonWalter Reed Army Institute of Research, Silver Spring, MD, USA.
Brooke AugustineWalter Reed Army Institute of Research, Silver Spring, MD, USA.
Charla AndrewsVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Galina V YamshchikovVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Somia HickmanVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Steven SchechHenry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Jack N HutterWalter Reed Army Institute of Research, Silver Spring, MD, USA.
Paul T ScottWalter Reed Army Institute of Research, Silver Spring, MD, USA.
Paige E WatermanWalter Reed Army Institute of Research, Silver Spring, MD, USA.
Mihret F AmareHenry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Victoria KiokoHenry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Casey StormeHenry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Kayvon ModjarradWalter Reed Army Institute of Research, Silver Spring, MD, USA.
Melanie D McCauleyHenry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Merlin L RobbHenry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Martin R GaudinskiVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ingelise J GordonVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
LaSonji A HolmanVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Alicia T WidgeVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Larisa StromVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Myra HappeVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Josephine H CoxVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Sandra VazquezVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Daphne A StanleyVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Tamar MurrayVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Caitlyn N M DulanVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ruth HunegnawVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Sandeep R NarpalaVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Phillip A SwansonVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Manjula BasappaVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jagada ThillainathanVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Marcelino PadillaVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Britta FlachVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Sarah O'ConnellVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Olga TrofymenkoVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Patricia MorganVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Emily E CoatesVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jason G GallVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Adrian B McDermottVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Richard A KoupVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
John R MascolaVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Aurélie PloquinVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Nancy J SullivanVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Julie A AkeWalter Reed Army Institute of Research, Silver Spring, MD, USA.
Julie E LedgerwoodVaccine Research Center, and Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
RV 507 Study Team
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · USWalter Reed Army Institute of Research · USHenry M. Jackson Foundation · US
Funding
Vaccine Immunology ProgramZIAAI005143 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2019 to 2025
$51.8MMarburg Vaccine DevelopmentZIAAI005080 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SULLIVAN, NANCY J · 2009 to 2023
$8.6MIntramural NIH HHS Z99 AI999999
Abstract
backgroundWHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg) in healthy adults.
methodsWe did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18-50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 10
findingsBetween Oct 9, 2018, and Jan 31, 2019, 40 healthy adults were enrolled and assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 10
interpretationThis first-in-human trial of this cAd3-Marburg vaccine showed the agent is safe and immunogenic, with a safety profile similar to previously tested cAd3-vectored filovirus vaccines. 95% of participants produced a glycoprotein-specific antibody response at 4 weeks after a single vaccination, which remained in 70% of participants at 48 weeks. These findings represent a crucial step in the development of a vaccine for emergency deployment against a re-emerging pathogen that has recently expanded its reach to new regions.
fundingNational Institutes of Health.
Indexed as
Adenoviruses, SimianMarburgvirusAdenoviridaeAdultAnimalsAntibodies, ViralDouble-Blind MethodGlycoproteinsHumansPan troglodytesVaccines, SyntheticAntibodies, ViralGlycoproteinsVaccines, Synthetic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.